Device was received for evaluation.Explant date is currently unknown.Upon receipt, the device interrogation revealed the eri battery status, one charging cycle was documented to the devices memory.The device was subjected to an electrical analysis.The amount of charge taken from the battery was verified and proven to be consistent with the eri battery status.The current consumption of the icd was measured and found to be elevated.Next, the ability of the device to deliver therapies was verified.The anti-bradycardia pacing pulses proved to be normal and in amplitude and frequency as programmed.A fibrillation signal was applied and the device delivered a defibrillation shock as specified, documenting a normal and expected sensing and shock delivery.In particular, the specified energy level was reached.In a next step the icd was opened and the inner assembly was inspected.The visual inspection of the inner assembly showed no anomalies.Further electrical investigations revealed that an integrated circuit of the electronic module was damaged, causing an elevated current consumption, draining the battery.The manufacturing process for this device was re-investigated and all production steps were performed accordingly.There was no sign of any inconsistency during the manufacturing process.Particularly the final acceptance test proved the device functions to be as specified.In conclusion, an elevated current consumption due to a damaged integrated circuit was identified to be the root cause for the clinical observation.The manufacturing records document a normal device production.It is therefore assumed that the high current condition occurred after the device shipment, however the date of occurrence was not determinable.All therapy functions of the icd were available while the device was implanted and in service.
|